United States: GNC Lawsuit Reflects FDA's Crackdown On Dietary Supplement Industry

The Oregon Attorney General's Office hit General Nutrition Centers (GNC) with a lawsuit last week alleging that the company knowingly sold supplements that contained FDA-banned ingredients. The action should serve as a cautionary tale to the dietary supplement industry facing renewed FDA scrutiny. Although denied by GNC, the accusations and allegations continue as evidenced by the complaint filed by the Oregon State Attorney General and recent FDA Warning Letters, including several issued six months prior that specifically addressed one of the suspect ingredients in Oregon.

The impact on the industry is yet to be fully known, however, the dietary supplement industry can be assured that if nothing else, there is a heightened awareness of its activities by both public and government entities. In light of these recent events, supplement manufactures should conduct a careful internal review of ingredients, labels and new dietary ingredient filings.

FDA Warning Letters and the GNC Lawsuit

In April 2015, the FDA issued a series of warning letters to dietary supplement manufacturers and sellers in regards to the inclusion of an unapproved ingredient, Beta-methylphenethylamine, also known as βMePEA, or BMPEA. Some of these companies listed BMPEA as an ingredient on their product's ingredient listings, while others hid the product behind claims that BMPEA is an extract of the Acacia rigidula plant. These FDA warning letters asserted that BMPEA is not an approved dietary ingredient as defined by 21 U.S.C. § 321(ff)(1). The FDA also stated that BMPEA is not an approved food additive, not approved for use in dietary supplements, with no evidence that the substance is or should be considered Generally Recognized as Safe (GRAS). Additionally, the letter reported that FDA research found that Acacia rigidula does not contain amphetamines like BMPEA. The warning letters stated that products containing BMPEA disguised as the plant extract were all, therefore, misbranded under 21 U.S.C. § 343(a)(1).

Since these warning letters, many of these products have been taken off the market or reformulated. However, Oregon Attorney General Ellen Rosenbaum filed a lawsuit on Oct. 22, 2015 against General Nutrition Centers, or GNC, for continuing to sell BMPEA under the guise of Acacia rigidula in 22 of its workout and fat-burning supplement products. The 30-page complaint goes into significant detail regarding the nature of BMPEA and claims that GNC violated the Oregon Unlawful Trade Practices Act (UTPA) by:

"misrepresenting that various products that GNC sold in Oregon were lawful dietary supplements when in fact those products were adulterated and unlawful because they contained either picamilon or BMPEA, dangerous ingredients that do not meet the legal definition of a dietary ingredient and may not be lawfully used in dietary supplements."

The two cited ingredients, picamilon and BMPEA, are not approved dietary ingredients or food additives by the FDA. In fact, BMPEA, according to Rosenbaum's lawsuit, is a synthetic chemical similar to amphetamine and banned by the World Anti-Doping Organization.

Finally, the lawsuit provides several email transcripts claiming to show that not only were GNC representatives aware that picamion and BMPEA were unapproved components of their products, but may also show that GNC continued to sell products containing picamilon and BMPEA after being warned by the Oregon AG office in June.

New Dietary Ingredients and Substances for Use in Dietary Supplements

Under 21 C.F.R. § 321(ff)(1), a dietary ingredient is defined as a vitamin; mineral; herb or other botanical; amino acid; dietary substance for use by man to supplement the diet by increasing the total dietary intake; or a concentrate, metabolite, constituent, extract, or combination of the preceding substances. In order to use a new dietary ingredient in a dietary supplement, the FDA requires that companies notify the FDA prior to selling the supplement containing it, and be able to provide to the FDA scientific evidence supporting the use of the dietary ingredient in the supplement.

However, in order to be approved for use in a supplement, a new dietary ingredient must actually be a dietary ingredient. The problem with the picamilon and BMPEA allegedly found in GNC's products is that the FDA has explicitly found that they are not dietary ingredients, as neither fits the description of any of the items in §321(ff)(1), as defined above. As a result, the FDA found in its warning letters that including either in a supplement's list of dietary ingredients renders the supplement misbranded, as it would then contain misleading or untruthful statements.

The only other way a non-food ingredient (food ingredients are defined as those substances normally eaten as foods on their own by humans, and are not subject to dietary ingredient requirements or GRAS certification) can be included in a human dietary supplement is if it has been found to be GRAS, either by the FDA, on its own or as a result of an industry petition. It is important to note that in its warning letters, the FDA issued an invitation to the warned companies to provide supporting evidence by which the FDA could find picamilon or BMPEA to be GRAS. To date, no such findings have been published by the FDA. Since neither picamilon nor BMPEA are recognized as GRAS products by the FDA, and are not the subject of a new dietary ingredient notice to the FDA, they currently cannot be used in human dietary supplements.

This Oregon suit is simply the next step in an ongoing nationwide investigation into the dietary supplement industry, which began in earnest with the FDA's announcement on Nov. 18, 2013 of its testing of 21 dietary supplements that were labeled as "all natural." The FDA found that nine of those tested to contained BMPEA and others had unapproved, synthetic substances not tested for safety in humans. The FDA subsequently seized $2 million in supplements from one manufacturer alone as a result of the Agency's testing and investigation.

These FDA enforcement actions and investigations continued with several new warning letters to dietary supplement companies issued in April 2015 for selling products containing unapproved ingredients. Again, the FDA found that by including these unapproved substances, the supplements that contained them were rendered misbranded or adulterated. The dietary supplement industry, through these FDA enforcement actions, is on notice that its products are under increased national scrutiny, and an internal review of ingredients, labels, and new dietary ingredient filings is well-warranted.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions